EXOZ EXOZYMES INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2010788 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-21.6%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-268.1%
ROA-149.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-41.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.62M | $1.44M | $1.12M | $1.11M | $1.22M | $802,991 | $575,016 | $630,303 |
| SG&A expense | $1.43M | $1.52M | $1.27M | $1.58M | $1.31M | $1.75M | $1.38M | $1.35M |
| Operating income | -$3.05M | -$2.95M | -$2.39M | -$2.70M | -$2.52M | -$2.55M | -$1.95M | -$1.98M |
| Pretax income | -$2.24M | -$2.88M | -$2.37M | -$2.76M | -$2.29M | -$2.36M | -$1.86M | -$1.84M |
| Net income | -$2.24M | -$2.88M | -$2.37M | -$2.66M | -$2.29M | -$2.36M | -$1.86M | -$1.84M |
| EBITDA | -$2.96M | -$2.88M | -$2.31M | -$2.62M | -$2.45M | -$2.48M | -$1.88M | -$1.92M |
| EPS (basic) | -0.24 | -0.33 | -0.28 | — | -0.27 | -0.28 | -0.22 | — |
| EPS (diluted) | -0.24 | -0.33 | -0.28 | — | -0.27 | -0.28 | -0.22 | — |
| Weighted avg. shares (diluted) | 9.29M | 8.66M | 8.46M | — | 8.39M | 8.38M | 8.37M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.26M | $5.65M | $1.44M | $3.04M | $5.10M | $6.99M | $8.51M | $9.72M |
| Current assets | $3.91M | $6.17M | $2.09M | $3.94M | $5.61M | $7.53M | $9.42M | $10.82M |
| PP&E, net | $895,929 | $670,908 | $747,858 | $764,401 | $763,012 | $821,305 | $842,990 | $882,445 |
| Total assets | $5.86M | $7.98M | $4.02M | $5.97M | $7.72M | $9.68M | $11.53M | $13.03M |
| Current liabilities | $1.70M | $1.62M | $1.58M | $1.57M | $1.24M | $1.22M | $1.44M | $1.33M |
| Total liabilities | $3.67M | $4.33M | $2.49M | $2.57M | $2.34M | $2.44M | $2.64M | $2.61M |
| Shareholders' equity | $2.19M | $3.65M | $1.53M | $3.40M | $5.37M | $7.24M | $8.88M | $10.42M |
| Shares outstanding | 9.30M | 9.28M | 8.48M | 8.41M | 8.39M | 8.39M | 8.37M | 8.37M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.22M | -$1.64M | -$1.52M | -$1.97M | -$1.86M | -$1.54M | -$1.13M | -$5.71M |
| Capital expenditure | $309,980 | -$1 | $57,604 | $74,988 | $13,310 | $50,573 | $31,046 | $210,406 |
| Free cash flow | -$2.53M | -$1.64M | -$1.58M | -$2.05M | -$1.87M | -$1.59M | -$1.16M | -$5.92M |
| Investing cash flow | -$164,765 | $1 | -$57,604 | -$74,990 | -$13,308 | -$30,874 | -$31,046 | -$210,407 |
| Financing cash flow | -$7,407 | $5.85M | -$12,736 | -$10,554 | — | — | -$43,254 | $15.40M |
| Depreciation & amortization | $84,959 | $76,949 | $74,147 | $73,599 | $71,603 | $72,256 | $70,503 | $67,567 |
| Stock-based compensation | $775,871 | $1.22M | $501,098 | $677,866 | $425,708 | $567,254 | $317,277 | $317,277 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.